Paper39796175
The Emerging Predictive and Prognostic Role of Aggressive-Variant-Associated Tumor Suppressor Genes Across Prostate Cancer Stages.
Pedrani M and 12 others. Int J Mol Sci, 2025. Cited by 10 papers, by iCite.
Cite this record
ConductScience Library. The Emerging Predictive and Prognostic Role of Aggressive-Variant-Associated Tumor Suppressor Genes Across Prostate Cancer Stages. Papers, record 39796175. Release papers-2026-11-12-0.1.0, 12 Nov 2026. https://conductscience.org/library/papers/39796175
- Sources
- 11 sources
- Release
- papers-2026-11-12-0.1.0
Paper
PubMed's record of the paper, with iCite's citation figures. No abstract is shown.
- Title
- The Emerging Predictive and Prognostic Role of Aggressive-Variant-Associated Tumor Suppressor Genes Across Prostate Cancer Stages.
- PubMed
Topics9
NLM's MeSH indexing of the paper, its major topics first.
| MeSH term | Major |
|---|---|
| Prostatic Neoplasms | Major topic |
| Biomarkers, Tumor | Major topic |
| PTEN Phosphohydrolase | Major topic |
| Humans | |
| Male | |
| Prognosis | |
| Genes, Tumor Suppressor | |
| Neoplasm Staging | |
| Tumor Suppressor Protein p53 |
Source PubMed
References207
The papers the reference list in PubMed's record names, those in our copy of PubMed, in the list's order.
| Order | PMID | Title | Journal | Year | In Papers | Source |
|---|---|---|---|---|---|---|
| 1 | 37003085 | Management of patients with advanced prostate cancer-metastatic and/or castration-resistant prostate cancer: Report of the Advanced Prostate Cancer Consensus Conference (APCCC) 2022. | Eur J Cancer | 2023 | https://conductscience.org/library/papers/37003085 | PubMed |
| 2 | 26000489 | Integrative clinical genomics of advanced prostate cancer. | Cell | 2015 | https://conductscience.org/library/papers/26000489 | PubMed |
| 3 | 22000013 | Coding-independent regulation of the tumor suppressor PTEN by competing endogenous mRNAs. | Cell | 2011 | https://conductscience.org/library/papers/22000013 | PubMed |
| 4 | 35176163 | A Phase Ib/II Study of the CDK4/6 Inhibitor Ribociclib in Combination with Docetaxel plus Prednisone in Metastatic Castration-Resistant Prostate Cancer. | Clin Cancer Res | 2022 | https://conductscience.org/library/papers/35176163 | PubMed |
| 5 | 39577422 | Elucidating acquired PARP inhibitor resistance in advanced prostate cancer. | Cancer Cell | 2024 | https://conductscience.org/library/papers/39577422 | PubMed |
| 6 | 28411207 | Transdifferentiation as a Mechanism of Treatment Resistance in a Mouse Model of Castration-Resistant Prostate Cancer. | Cancer Discov | 2017 | https://conductscience.org/library/papers/28411207 | PubMed |
| 7 | 38729054 | Capivasertib in combination with enzalutamide for metastatic castration resistant prostate cancer after docetaxel and abiraterone: Results from the randomized phase II RE-AKT trial. | Eur J Cancer | 2024 | https://conductscience.org/library/papers/38729054 | PubMed |
| 8 | 23222491 | Cytoplasmic PTEN protein loss distinguishes intraductal carcinoma of the prostate from high-grade prostatic intraepithelial neoplasia. | Mod Pathol | 2013 | https://conductscience.org/library/papers/23222491 | PubMed |
| 9 | 35179959 | RB1 loss overrides PARP inhibitor sensitivity driven by RNASEH2B loss in prostate cancer. | Sci Adv | 2022 | https://conductscience.org/library/papers/35179959 | PubMed |
| 10 | 23649003 | Platinum-based chemotherapy for variant castrate-resistant prostate cancer. | Clin Cancer Res | 2013 | https://conductscience.org/library/papers/23649003 | PubMed |
| 11 | 30037818 | Randomized Phase II Study Evaluating Akt Blockade with Ipatasertib, in Combination with Abiraterone, in Patients with Metastatic Prostate Cancer with and without PTEN Loss. | Clin Cancer Res | 2019 | https://conductscience.org/library/papers/30037818 | PubMed |
| 12 | 15472903 | Expression patterns of potential therapeutic targets in prostate cancer. | Int J Cancer | 2005 | https://conductscience.org/library/papers/15472903 | PubMed |
| 13 | 25691773 | Novel actions of next-generation taxanes benefit advanced stages of prostate cancer. | Clin Cancer Res | 2015 | https://conductscience.org/library/papers/25691773 | PubMed |
| 14 | 38136389 | Evaluation of the Aggressive-Variant Prostate Cancer Molecular Signature in Clinical Laboratory Improvement Amendments (CLIA) Environments. | Cancers (Basel) | 2023 | https://conductscience.org/library/papers/38136389 | PubMed |
| 15 | 30553611 | Compound Genomic Alterations of TP53, PTEN, and RB1 Tumor Suppressors in Localized and Metastatic Prostate Cancer. | Eur Urol | 2019 | https://conductscience.org/library/papers/30553611 | PubMed |
| 16 | 30033370 | Genomic Hallmarks and Structural Variation in Metastatic Prostate Cancer. | Cell | 2018 | https://conductscience.org/library/papers/30033370 | PubMed |
| 17 | 25056375 | Evidence for molecular differences in prostate cancer between African American and Caucasian men. | Clin Cancer Res | 2014 | https://conductscience.org/library/papers/25056375 | PubMed |
| 18 | 28068672 | Genomic hallmarks of localized, non-indolent prostate cancer. | Nature | 2017 | https://conductscience.org/library/papers/28068672 | PubMed |
| 19 | 23545904 | Assessing the order of critical alterations in prostate cancer development and progression by IHC: further evidence that PTEN loss occurs subsequent to ERG gene fusion. | Prostate Cancer Prostatic Dis | 2013 | https://conductscience.org/library/papers/23545904 | PubMed |
| 20 | 35688662 | Overall Survival Update for Patients with Metastatic Castration-resistant Prostate Cancer Treated with Capivasertib and Docetaxel in the Phase 2 ProCAID Clinical Trial. | Eur Urol | 2022 | https://conductscience.org/library/papers/35688662 | PubMed |
Cited by10
The papers in our copy of PubMed whose reference list names this one, newest first. iCite, which reads more sources, counts 10 citations.
| PMID | Title | Journal | Year | In Papers | Source |
|---|---|---|---|---|---|
| 42794743 | Young Aggressive Prostate Tumors Exhibit Increased Genomic Instability and an Exploratory RNA-CNA-Concordant Transcriptomic Pattern. | Int J Mol Sci | 2026 | https://conductscience.org/library/papers/42794743 | PubMed |
| 42427857 | Clinical and genomic predictors of sipuleucel-T outcomes in men with metastatic androgen pathway modulator resistant prostate cancer. | Res Sq | 2026 | https://conductscience.org/library/papers/42427857 | PubMed |
| 42279286 | Circulating Tumor DNA as Emerging Predictive and Prognostic Biomarker in Prostate Cancer. | Cancers (Basel) | 2026 | https://conductscience.org/library/papers/42279286 | PubMed |
| 42246034 | Toward the genetic landscape of prostate cancer in India: insights from whole-exome and low-pass whole-genome sequencing of formalin-fixed paraffin-embedded tumor tissues. | Front Syst Biol | 2026 | https://conductscience.org/library/papers/42246034 | PubMed |
| 42028056 | Penile metastasis from prostate adenocarcinoma: A case report and review of the literature. | SAGE Open Med Case Rep | 2026 | https://conductscience.org/library/papers/42028056 | PubMed |
| 41878526 | Real-world precision medicine data in metastatic prostate cancer - a retrospective cohort study. | Front Oncol | 2026 | https://conductscience.org/library/papers/41878526 | PubMed |
| 41543663 | The role of multimodality imaging in selection, response assessment, and follow-up of patients receiving 177Lutetium-PSMA-therapy. | Insights Imaging | 2026 | https://conductscience.org/library/papers/41543663 | PubMed |
| 41375007 | Predicting Toxicities and Survival Outcomes in De Novo Metastatic Hormone-Sensitive Prostate Cancer Using Clinical Features, Routine Blood Tests and Their Early Variations. | Cancers (Basel) | 2025 | https://conductscience.org/library/papers/41375007 | PubMed |
| 40508118 | Integrating Aggressive-Variant Prostate Cancer-Associated Tumor Suppressor Gene Status with Clinical Variables to Refine Prognosis and Predict Androgen Receptor Pathway Inhibitor Response in Metastatic Hormone-Sensitive Setting. | Int J Mol Sci | 2025 | https://conductscience.org/library/papers/40508118 | PubMed |
| 40427204 | Echolaser Focal Treatment for Prostate Cancer Guided by Fiducial Marker Placement. | Cancers (Basel) | 2025 | https://conductscience.org/library/papers/40427204 | PubMed |
Genes4
The genes the Gene search release ties to the paper: Swiss-Prot's references first, then PubTator's text mining.
| Gene | NCBI Gene ID | Linked by | In Genes | Source |
|---|---|---|---|---|
| PTEN | 5728 | PubTator's text mining | https://conductscience.org/library/genes/5728 | NCBI Gene |
| RB1 | 5925 | PubTator's text mining | https://conductscience.org/library/genes/5925 | NCBI Gene |
| TP53 | 7157 | PubTator's text mining | https://conductscience.org/library/genes/7157 | NCBI Gene |
| TWSG1 | 57045 | PubTator's text mining | https://conductscience.org/library/genes/57045 | NCBI Gene |
Data dates
The date of each source this release read.
- Trials
- 2026-11-12
- Gene search
- 2026-11-11
- Pipelines
- 2026-09-18
None in this release
- Grants
- Trials
- Comments and corrections
- Drugs
- Data
Sources 11
- ChEMBL, through Open TargetsCC BY-SA 3.0
- ClinicalTrials.govNo license stated
- HGNCCC0
- iCiteCC BY 4.0
- NCBI GenePublic domain (US government)
- NIH RePORTER's grant and paper linksPublic domain
- Open TargetsCC0 1.0
- PMC's ID filePublic domain (US government)
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0
Each source's terms
- ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- ClinicalTrials.govnone stated
- HGNCCC0: https://www.genenames.org/about/license/
- iCiteCC BY 4.0
- NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- NIH RePORTER's grant and paper linksPublic domain (NIH RePORTER)
- Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- PMC's ID fileNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this paper from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/papers/v1/39796175
GET https://conductscience.org/api/papers/v1/39796175/references?page=2